var data={"title":"Progestin-only pills (POPs) for contraception","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Progestin-only pills (POPs) for contraception</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/contributors\" class=\"contributor contributor_credentials\">Andrew M Kaunitz, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/contributors\" class=\"contributor contributor_credentials\">Courtney A Schreiber, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/contributors\" class=\"contributor contributor_credentials\">Kristen Eckler, MD, FACOG</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 02, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Progestin-only contraception is an option for women in whom an estrogen-containing contraceptive is either contraindicated or causes additional health concerns. In addition to progestin-only pills, other types of progestin-only contraceptives include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Progestin injections (see <a href=\"topic.htm?path=depot-medroxyprogesterone-acetate-for-contraception\" class=\"medical medical_review\">&quot;Depot medroxyprogesterone acetate for contraception&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Progestin implants (eg, Nexplanon, Jadelle) (see <a href=\"topic.htm?path=etonogestrel-contraceptive-implant\" class=\"medical medical_review\">&quot;Etonogestrel contraceptive implant&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intrauterine contraception (eg, Mirena, Skyla) (see <a href=\"topic.htm?path=intrauterine-contraception-candidates-and-device-selection\" class=\"medical medical_review\">&quot;Intrauterine contraception: Candidates and device selection&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H15275427\"><span class=\"h1\">FORMULATIONS</span></p><p class=\"headingAnchor\" id=\"H15275506\"><span class=\"h2\">Norethindrone</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Only one progestin-only contraceptive pill (POP) formulation is marketed in the United States: <a href=\"topic.htm?path=norethindrone-drug-information\" class=\"drug drug_general\">norethindrone</a> 0.35 mg tablets (commercial names include Camila and Errin). The progestin dose is substantially lower than the dose in any combination oral contraceptive. It is dispensed in packs of 28 active pills, which are taken continuously (ie, no pill free or nonhormonal pill week) [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/1\" class=\"abstract_t\">1</a>]. <strong>Unless otherwise noted, the information on POPs in this topic primarily applies to norethindrone POPs.</strong></p><p class=\"headingAnchor\" id=\"H15275512\"><span class=\"h2\">Desogestrel</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In some areas of the world, desogestrel is available as a 75 mcg POP formulation [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/2\" class=\"abstract_t\">2</a>]. This formulation has significant differences from the POP discussed in this topic: the main mechanism of action is inhibition of ovulation, contraceptive efficacy is as high as that with estrogen-progestin contraceptive pills, and intake delay of up to 12 hours does not affect its contraceptive efficacy [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/3\" class=\"abstract_t\">3</a>]. <strong>Unless otherwise noted, the information on POPs in this topic applies to </strong><a href=\"topic.htm?path=norethindrone-drug-information\" class=\"drug drug_general\">norethindrone</a><strong> POPs.</strong></p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">MECHANISM OF ACTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Progestin-only contraceptive pills (POPs) work by thickening cervical mucus, suppressing ovulation, and thinning the endometrium. In contrast to estrogen-progestin oral contraceptive pills and desogestrel POPs, ovulation is not consistently suppressed with <a href=\"topic.htm?path=norethindrone-drug-information\" class=\"drug drug_general\">norethindrone</a> POPs [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/4\" class=\"abstract_t\">4</a>]. Therefore, the effects of norethindrone POPs on cervical mucus and endometrium represent the critical factors in prevention of conception [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/5\" class=\"abstract_t\">5</a>]. Within hours of administration, all POPs reduce the volume of cervical mucus and increase its viscosity, which prevents sperm from passing through the cervical canal and endometrial cavity. These changes persist for 20 hours [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/6,7\" class=\"abstract_t\">6,7</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">EFFICACY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>National survey data used to estimate contraceptive failure rates with typical use have not distinguished between users of estrogen-progestin contraceptive pills (9 percent failure rate in first year of use) and progestin-only contraceptive pills (POPs). Because the great majority of oral contraceptives used in the United States represent estrogen-progestin contraceptive pills and the failure rate with POPs is likely to be higher than with estrogen-progestin contraceptive pills, the typical user failure rate with POPs is likely to be higher than 9 percent [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/8\" class=\"abstract_t\">8</a>].</p><p>In the United States, many women who use POPs are subfertile as a result of breastfeeding or older reproductive age. Thus, the failure rate of POPs in these populations is lower than in more fertile populations [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/9,10\" class=\"abstract_t\">9,10</a>]. Some clinicians have speculated that taking a daily dose of two or more POP tablets (two tablets as a single dose) might increase the contraceptive efficacy of POPs in young, nonlactating women who are presumably highly fecund [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/1,11\" class=\"abstract_t\">1,11</a>]. The author prescribes the two-pill regimen to women with normal fertility (ie, not postpartum, lactating, or perimenopausal); the additional cost is a disadvantage of this approach. There are no published data regarding this off-label contraceptive strategy. There are also no data regarding contraceptive efficacy in obese fertile women.</p><p>An oral formulation combining 1 mg of <a href=\"topic.htm?path=norethindrone-drug-information\" class=\"drug drug_general\">norethindrone</a> acetate and 5 mcg of ethinyl estradiol (commercial name Jinteli) is marketed for the treatment of menopausal symptoms [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/12\" class=\"abstract_t\">12</a>]. Because this dose of norethindrone acetate appears sufficient to consistently suppress ovulation and the dose of estrogen is small, some clinicians prescribe this combination medication off-label to women requiring contraception who medically are not candidates for conventional combination estrogen-progestin contraceptives. Such women should be counseled that norethindrone acetate 1 <span class=\"nowrap\">mg/ethinyl</span> estradiol 5 mcg is not approved for contraceptive use and that condom back-up is recommended. (Note: the progestational impact of norethindrone acetate 1 mg is similar to that of norethindrone 1 mg). (See <a href=\"topic.htm?path=risks-and-side-effects-associated-with-estrogen-progestin-contraceptives\" class=\"medical medical_review\">&quot;Risks and side effects associated with estrogen-progestin contraceptives&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">ADMINISTRATION</span></p><p class=\"headingAnchor\" id=\"H407447885\"><span class=\"h2\">Candidates for use of POPs</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most women can use progestin-only contraceptive pills (POPs). We agree with the <a href=\"http://www.cdc.gov/reproductivehealth/contraception/pdf/summary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=jEVGVo6WqsDq698K1C6vDPPjIqTfzg54vW4qWS3doblDMO+X3NN/ro6R0xwK/I6IOwBh6DyNhV/q6vrv3T8nCaRCrZsEC+Wz9FPYFmXFzWEhd9uzeVTKQGeWKf6mT23Z1X5qsRVoFq27I5l+8ZoObQ==&amp;TOPIC_ID=5461\" target=\"_blank\" class=\"external\">Centers for Disease Control and Prevention (CDC)</a> guidelines regarding use of POPs in women with medical comorbidities.</p><p class=\"headingAnchor\" id=\"H1073173877\"><span class=\"h3\">Women in whom estrogen is contraindicated</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>POPs are a good option for women in whom an estrogen-containing contraceptive is either contraindicated or causes additional health concerns (eg, migraine with aura, &ge;35 years of age and smoking &ge;15 <span class=\"nowrap\">cigarettes/day)</span>. Because their impact on recurrence risk in women with current breast cancer is unknown, hormonal contraceptives (estrogen-progestin or progestin-only) are contraindicated in this population.</p><p class=\"headingAnchor\" id=\"H14876562\"><span class=\"h2\">Patient evaluation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Physical examination and laboratory tests are not indicated before beginning POPs in women who are appropriate candidates for this method.</p><p class=\"headingAnchor\" id=\"H407447879\"><span class=\"h2\">Initiation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We suggest that POPs be initiated on the first day of menses; back-up contraceptive is not necessary if POPs are started within the first five days of start of menses [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/13\" class=\"abstract_t\">13</a>]. Because of the short duration of action and the short half-life of POPs, it is <strong>essential</strong> that the pill be taken <strong>at the same time each day</strong> to maximize contraceptive efficacy [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/14-16\" class=\"abstract_t\">14-16</a>].</p><p>Some clinicians initiate POPs at any time in the cycle, as long as the clinician is reasonably certain that the patient is not pregnant (<a href=\"image.htm?imageKey=OBGYN%2F67567\" class=\"graphic graphic_table graphicRef67567 \">table 1</a>). Back-up contraception is needed if she is &gt;5 days from onset of menses. POP is the only method where the 2013 US Selected Practice Recommendations for Contraceptive Use recommend two days rather than seven days of back-up contraception, presumably because of the rapid effect of the POP on cervical mucus. Clinically, it is simpler to advise all women initiating contraception more than five days from onset of menses to use back-up contraception (or abstinence) for seven days.</p><p class=\"headingAnchor\" id=\"H407447977\"><span class=\"h2\">Timing doses and missed pills</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As stated above, it is <strong>essential</strong> that the pill be taken at the same time each day to maximize contraceptive efficacy [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/14-16\" class=\"abstract_t\">14-16</a>]. A back-up contraceptive (eg, condoms) should be used or the woman should abstain from sex for at least two days if the POP is taken <strong>more than three hours late</strong> <strong>or missed</strong> on any given day. The patient should also resume taking daily POPs as soon as possible, even if this means that she takes two pills on one day (the missed pill and the usual time pill) [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/13\" class=\"abstract_t\">13</a>]. Back-up <span class=\"nowrap\">contraception/abstinence</span> can be discontinued after POPs have been taken correctly, on time, for two consecutive days.</p><p>Vomiting or severe diarrhea within three hours of taking a POP may decrease contraceptive effectiveness. These clinical scenarios are managed in a similar way as a late or missed pill. The woman should continue taking POPs daily at the same time each day and use back-up contraception (condoms) or avoid sex until two days after vomiting or diarrhea has resolved [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/13\" class=\"abstract_t\">13</a>].</p><p class=\"headingAnchor\" id=\"H407447920\"><span class=\"h2\">Reducing barriers to use</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Providing or prescribing a one-year supply of POPs enhances continuation rates [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/17\" class=\"abstract_t\">17</a>].</p><p class=\"headingAnchor\" id=\"H407447946\"><span class=\"h2\">Follow-up</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Routine follow-up is unnecessary [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/13\" class=\"abstract_t\">13</a>]. The woman should return if she has concerns about the method, side effects, a change in health status that might affect use of hormonal contraception, or if she wants to switch methods.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">SIDE EFFECTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Unscheduled bleeding and changes in menses are the most common side effects associated with progestin-only contraceptive pills (POPs); an increased prevalence of follicular ovarian cysts [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/18\" class=\"abstract_t\">18</a>] and acne flare [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/5\" class=\"abstract_t\">5</a>] have also been reported. POPs do not cause significant weight gain [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/19\" class=\"abstract_t\">19</a>] and are not likely to increase headache frequency [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/20\" class=\"abstract_t\">20</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Unscheduled bleeding and menstrual changes</strong> &ndash;<strong> </strong>As with all continuous progestin-only contraceptives, menstrual irregularities are common in POP users and represent the most frequent cause for contraceptive discontinuation. Unscheduled bleeding and spotting are the most common bleeding patterns during POP use, and prospective, as well as current, users should be counseled accordingly. POP users have more frequent, longer episodes and shorter, less predictable intervals than combined pill users [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/21\" class=\"abstract_t\">21</a>], but up to half of users experience a mostly regular monthly bleeding pattern [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/22\" class=\"abstract_t\">22</a>]. Amenorrhea and prolonged episodes of bleeding also occur, but less frequently than in depot-medroxyprogesterone acetate (DMPA) users [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/23\" class=\"abstract_t\">23</a>].</p><p/><p class=\"bulletIndent1\">Interpreting signs and symptoms of pregnancy, whether intrauterine or extrauterine, can be challenging in POP users. Pregnancy testing is appropriate for POP users experiencing nausea, breast tenderness, a change in bleeding pattern, or lower abdominal pain.</p><p/><p class=\"bulletIndent1\">Unscheduled bleeding and its management in POP users are discussed in more detail separately. (See <a href=\"topic.htm?path=management-of-unscheduled-bleeding-in-women-using-contraception#H13\" class=\"medical medical_review\">&quot;Management of unscheduled bleeding in women using contraception&quot;, section on 'Progestin pills'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Follicular cysts</strong> &ndash; Sonographic studies have observed that follicular cysts are more common in POP users than women not using hormones [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/18\" class=\"abstract_t\">18</a>]. The follicular changes tend to increase and regress over time [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/24,25\" class=\"abstract_t\">24,25</a>]. No intervention is required in asymptomatic women, other than reassurance. POP users who have persistent concerns about ovarian follicular changes should be offered another method of contraception [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/5\" class=\"abstract_t\">5</a>].</p><p/><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">RISKS AND BENEFITS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Progestin-only contraception is an option for women in whom an estrogen-containing contraceptive is either contraindicated or causes additional health concerns. (See <a href=\"topic.htm?path=risks-and-side-effects-associated-with-estrogen-progestin-contraceptives\" class=\"medical medical_review\">&quot;Risks and side effects associated with estrogen-progestin contraceptives&quot;</a>.)</p><p>Although clinicians should familiarize themselves with the contraindications listed on package labeling for all medications they prescribe, progestin-only hormonal methods appear to be appropriate contraceptive choices for many women with contraindications to estrogen-containing contraceptives. Many of the contraindications listed in the package insert were established for estrogen-progestin contraceptive pills and then extrapolated to progestin-only methods because clinical trials have not evaluated the safety of the latter in women with contraindications to estrogen. (See <a href=\"topic.htm?path=risks-and-side-effects-associated-with-estrogen-progestin-contraceptives\" class=\"medical medical_review\">&quot;Risks and side effects associated with estrogen-progestin contraceptives&quot;</a>.)</p><p>Given the low dose of hormone, the failure rate of progestin-only contraceptive pills (POPs) in highly fertile women may be higher than that with other hormonal contraceptive methods. However, serious complications are less common than with combined estrogen-progestin contraceptives [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/26\" class=\"abstract_t\">26</a>], and the method is less invasive and more readily reversible than progestin injections, implants, and intrauterine contraception.</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Effect on cardiovascular risk</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>POPs have little effect on coagulation factors [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/27\" class=\"abstract_t\">27</a>], blood pressure [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/28,29\" class=\"abstract_t\">28,29</a>], or lipid levels [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/27,28,30,31\" class=\"abstract_t\">27,28,30,31</a>]. Large epidemiologic studies and a systematic review have not identified a statistically increased risk of stroke, myocardial infarction, or venous thromboembolism with use of POPs [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/32-37\" class=\"abstract_t\">32-37</a>]. In a case-control study of women with venous thromboembolism, use of POPs, the levonorgestrel-releasing intrauterine device, or the progestin-only contraceptive implant was not a significant risk factor for venous thromboembolism [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/36\" class=\"abstract_t\">36</a>]. Use of depot medroxyprogesterone (DMPA) injection was a significant risk factor, but the association was less robust than for estrogen-progestin contraceptives (OR 2.2 versus 5.3). Thus, we and others [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/38,39\" class=\"abstract_t\">38,39</a>] believe POPs represent a reasonable contraceptive choice for women at high risk of, or known, coronary artery disease, cerebrovascular disease, venous thromboembolic disease, hypertension, or other conditions in which use of contraceptive doses of estrogen are contraindicated. </p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Effect on carbohydrate metabolism</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>POPs are an appropriate contraceptive choice for women with diabetes, including those with vascular disease [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/39\" class=\"abstract_t\">39</a>]. Most studies have reported that POPs have little impact on carbohydrate metabolism [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/27,28,30,31\" class=\"abstract_t\">27,28,30,31</a>]. However, one study conducted in Latina women observed that lactating women with a history of gestational diabetes who used POPs postpartum had an elevated risk of being diagnosed with diabetes [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/40\" class=\"abstract_t\">40</a>]. After adjustment for potential confounding factors, the use of minipills almost tripled the risk of type 2 diabetes mellitus compared with equivalent use of low-dose estrogen-progestin contraceptive pills (adjusted relative risk, 2.87; 95% CI 1.57-5.27). Based on this one study, we suggest clinicians monitor glucose tolerance in high risk lactating women using POPs.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Ectopic pregnancy risk</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>POPs lower the overall risk of ectopic pregnancy, as well as intrauterine pregnancy, by preventing ovulation or conception. Since women taking POPs do not appear to have a higher absolute risk of ectopic pregnancy than women using no contraception, a history of ectopic pregnancy does not contraindicate POP use [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/1\" class=\"abstract_t\">1</a>]. However, if pregnancy occurs, the likelihood that the pregnancy is ectopic is higher in POP users than in women not using contraception (5 versus 2 percent) [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/41\" class=\"abstract_t\">41</a>].</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Effect on bone mineral density</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The only study assessing skeletal health in POP users was conducted in breast feeding women. Although breast feeding resulted in a reversible reduction in spinal bone mineral density in women using barrier contraception, the small amounts of hormone in the POP protected against this loss [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/42\" class=\"abstract_t\">42</a>].</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Older reproductive age women</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The reduced fecundity of women over age 35 to 40 years means they can expect high contraceptive efficacy with use of POPs [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/5\" class=\"abstract_t\">5</a>]. As discussed above, younger, highly fecund women who want to achieve high contraceptive efficacy with POPs may take two tablets (off-label) daily [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/1,11\" class=\"abstract_t\">1,11</a>]. (See <a href=\"#H3\" class=\"local\">'Efficacy'</a> above.)</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Effect on cancer risk</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Daily use of a progestin protects against development of endometrial cancer [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/43\" class=\"abstract_t\">43</a>]. There is little epidemiologic data on the effect of POPs on cancer risk. Available data suggest that associations between minipill use and reproductive cancers parallel known associations with estrogen-progestin contraceptive pills, in particular, breast cancer risk does not appear to be significantly different from that in nonusers [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/44\" class=\"abstract_t\">44</a>]. There is no information on ovarian cancer risk.</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h2\">Effect on sexually transmitted infections</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Use of POPs does not protect users from acquiring sexually transmitted infections. However, progestin-induced thickening and increased viscosity of cervical mucus has been hypothesized to inhibit ascent of bacteria and thus reduce the risk of development of pelvic inflammatory disease (PID).</p><p class=\"headingAnchor\" id=\"H1073173918\"><span class=\"h2\">Noncontraceptive benefits</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Use of POPs for management of dysmenorrhea, menorrhagia, or pelvic pain has not been studied. As discussed above, POPs protect against development of endometrial cancer and possibly against development of PID.</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h1\">USE AFTER ABORTION OR DELIVERY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Progestin-only contraceptive pills (POPs) may be initiated immediately postabortion or postdelivery, and should be initiated by three weeks after delivery to assure effectiveness [<a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/38,39,45\" class=\"abstract_t\">38,39,45</a>]. Breastfeeding is not a contraindication to use of POPs. Resumption of menses in a breastfeeding woman using POPs is a signal of increasing fecundability; such women may want to switch to a more effective contraceptive. Off-label use of two tablets of POPs daily is another option. (See <a href=\"#H3\" class=\"local\">'Efficacy'</a> above and <a href=\"topic.htm?path=postpartum-contraception-initiation-and-methods#H2218081431\" class=\"medical medical_review\">&quot;Postpartum contraception: Initiation and methods&quot;, section on 'Progestin-only methods'</a>.)</p><p class=\"headingAnchor\" id=\"H1789383836\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-contraception\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Contraception&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topic (see <a href=\"topic.htm?path=hormonal-methods-of-birth-control-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Hormonal methods of birth control (Beyond the Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H22\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Progestin-only contraception represents an option for women in whom an estrogen-containing contraceptive is either contraindicated or causes additional health concerns. One progestin-only oral contraceptive (POP) formulation is marketed in the United States: <a href=\"topic.htm?path=norethindrone-drug-information\" class=\"drug drug_general\">norethindrone</a> 0.35 mg tablets. The progestin dose is substantially lower than the dose in any combination oral contraceptive. The pills are dispensed in packs of 28 active pills, which are taken continuously (ie, no pill free or nonhormonal pill week). (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ovulation is not consistently suppressed; the effects of POPs on cervical mucus and endometrium are the critical factors in prevention of conception. (See <a href=\"#H2\" class=\"local\">'Mechanism of action'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The typical user failure rate with POPs is estimated to be over 9 percent. Women choosing POPs are often subfertile as a result of breast feeding or older reproductive age so the failure rate in these populations is thought to be lower than in more fertile populations. (See <a href=\"#H3\" class=\"local\">'Efficacy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It is <strong>essential that the pill be taken at the same time each day</strong> to maximize contraceptive efficacy. A back-up contraceptive (eg, condoms) should be used for at least two days if the POP is taken more than three hours late or forgotten on any given day. (See <a href=\"#H4\" class=\"local\">'Administration'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Menstrual irregularities are common in POP users and represent the most frequent cause for contraceptive discontinuation. (See <a href=\"#H5\" class=\"local\">'Side effects'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In contrast to package labeling, we agree with the <a href=\"http://www.cdc.gov/reproductivehealth/contraception/pdf/summary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=jEVGVo6WqsDq698K1C6vDPPjIqTfzg54vW4qWS3doblDMO+X3NN/ro6R0xwK/I6IOwBh6DyNhV/q6vrv3T8nCaRCrZsEC+Wz9FPYFmXFzWEhd9uzeVTKQGeWKf6mT23Z1X5qsRVoFq27I5l+8ZoObQ==&amp;TOPIC_ID=5461\" target=\"_blank\" class=\"external\">Centers for Disease Control and Prevention (CDC)</a> guidelines that POPs are an acceptable contraceptive option in women at increased risk of venous thrombosis. (See <a href=\"#H12\" class=\"local\">'Effect on cardiovascular risk'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/1\" class=\"nounderline abstract_t\">Kaunitz AM. Revisiting progestin-only OCs. Contemp Ob Gyn 1997; 91.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/2\" class=\"nounderline abstract_t\">Benagiano G, Primiero FM. Seventy-five microgram desogestrel minipill, a new perspective in estrogen-free contraception. Ann N Y Acad Sci 2003; 997:163.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/3\" class=\"nounderline abstract_t\">Korver T, Klipping C, Heger-Mahn D, et al. Maintenance of ovulation inhibition with the 75-microg desogestrel-only contraceptive pill (Cerazette) after scheduled 12-h delays in tablet intake. Contraception 2005; 71:8.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/4\" class=\"nounderline abstract_t\">Milsom I, Korver T. Ovulation incidence with oral contraceptives: a literature review. J Fam Plann Reprod Health Care 2008; 34:237.</a></li><li class=\"breakAll\">Speroff L, Darney P. A Clinical Guide for Contraception, 4th ed, Williams and Wilkins, Baltimore 2005.</li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/6\" class=\"nounderline abstract_t\">Lebech PE, Svendsen PA, Ostergaard E, Koch F. The effects of small doses of megestrol acetate on the cervical mucus. Acta Obstet Gynecol Scand 1969; 48:Suppl 3:22+.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/7\" class=\"nounderline abstract_t\">Wright SW, Fotherby K, Fairweather F. Effect of daily small doses of Norgestrel on ovarian function. J Obstet Gynaecol Br Commonw 1970; 77:65.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/8\" class=\"nounderline abstract_t\">Trussell J. Contraceptive failure in the United States. Contraception 2011; 83:397.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/9\" class=\"nounderline abstract_t\">Vessey MP, Lawless M, Yeates F, et al. Progestogen-only oral contraception. Findings in a large prospective study with special reference to effectiveness. Br J Fam Plann 1985; 10:117.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/10\" class=\"nounderline abstract_t\">Dunson TR, McLaurin VL, Grubb GS, Rosman AW. A multicenter clinical trial of a progestin-only oral contraceptive in lactating women. Contraception 1993; 47:23.</a></li><li class=\"breakAll\">Guillebaud J. Contraception: Your Questions Answered, 2nd ed, Churchill Livingstone Elsevier, New York 1993.</li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/12\" class=\"nounderline abstract_t\">Simon JA, Wysocki S, Brandman J, Axelsen K. A comparison of therapy continuation rates of different hormone replacement agents: a 9-month retrospective, longitudinal analysis of pharmacy claims among new users. Menopause 2003; 10:37.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/13\" class=\"nounderline abstract_t\">Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/14\" class=\"nounderline abstract_t\">Brenner PF, Mishell DR Jr, Stanczyk FZ, Goebelsmann U. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel. Am J Obstet Gynecol 1977; 129:133.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/15\" class=\"nounderline abstract_t\">Stanczyk FZ, Brenner PF, Mishell DR Jr, et al. A radioimmunoassay for norethindrone (NET): measurement of serum NET concentrations following ingestion of NET-containing oral contraceptive steroids. Contraception 1978; 18:615.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/16\" class=\"nounderline abstract_t\">Weiner E, Victor A, Johansson ED. Plasma levels of d-norgestrel after oral administration. Contraception 1976; 14:563.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/17\" class=\"nounderline abstract_t\">Steenland MW, Rodriguez MI, Marchbanks PA, Curtis KM. How does the number of oral contraceptive pill packs dispensed or prescribed affect continuation and other measures of consistent and correct use? A systematic review. Contraception 2013; 87:605.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/18\" class=\"nounderline abstract_t\">Tayob Y, Adams J, Jacobs HS, Guillebaud J. Ultrasound demonstration of increased frequency of functional ovarian cysts in women using progestogen-only oral contraception. Br J Obstet Gynaecol 1985; 92:1003.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/19\" class=\"nounderline abstract_t\">Lopez LM, Edelman A, Chen M, et al. Progestin-only contraceptives: effects on weight. Cochrane Database Syst Rev 2013; :CD008815.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/20\" class=\"nounderline abstract_t\">MacGregor EA. Contraception and headache. Headache 2013; 53:247.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/21\" class=\"nounderline abstract_t\">Belsey EM. Vaginal bleeding patterns among women using one natural and eight hormonal methods of contraception. Contraception 1988; 38:181.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/22\" class=\"nounderline abstract_t\">Broome M, Fotherby K. Clinical experience with the progestogen-only pill. Contraception 1990; 42:489.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/23\" class=\"nounderline abstract_t\">McCann MF, Potter LS. Progestin-only oral contraception: a comprehensive review. Contraception 1994; 50:S1.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/24\" class=\"nounderline abstract_t\">Shoupe D, Horenstein J, Mishell DR Jr, et al. Characteristics of ovarian follicular development in Norplant users. Fertil Steril 1991; 55:766.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/25\" class=\"nounderline abstract_t\">Barbosa I, Bakos O, Olsson SE, et al. Ovarian function during use of a levonorgestrel-releasing IUD. Contraception 1990; 42:51.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/26\" class=\"nounderline abstract_t\">Maximizing the use of the progestin minipill. Contracept Technol Update 1999; 20:19.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/27\" class=\"nounderline abstract_t\">Fotherby K. The progestogen-only pill and thrombosis. Br J Fam Plann 1989; 15:83.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/28\" class=\"nounderline abstract_t\">Ball MJ, Ashwell E, Gillmer MD. Progestagen-only oral contraceptives: comparison of the metabolic effects of levonorgestrel and norethisterone. Contraception 1991; 44:223.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/29\" class=\"nounderline abstract_t\">Hussain SF. Progestogen-only pills and high blood pressure: is there an association? A literature review. Contraception 2004; 69:89.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/30\" class=\"nounderline abstract_t\">Godsland IF, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990; 323:1375.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/31\" class=\"nounderline abstract_t\">Winkler UH. Blood coagulation and oral contraceptives. A critical review. Contraception 1998; 57:203.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/32\" class=\"nounderline abstract_t\">Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception 1998; 57:315.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/33\" class=\"nounderline abstract_t\">Heinemann LA, Assmann A, DoMinh T, Garbe E. Oral progestogen-only contraceptives and cardiovascular risk: results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Eur J Contracept Reprod Health Care 1999; 4:67.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/34\" class=\"nounderline abstract_t\">Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med 2004; 164:1965.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/35\" class=\"nounderline abstract_t\">Lidegaard &Oslash;, L&oslash;kkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012; 366:2257.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/36\" class=\"nounderline abstract_t\">Bergendal A, Persson I, Odeberg J, et al. Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes. Obstet Gynecol 2014; 124:600.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/37\" class=\"nounderline abstract_t\">Tepper NK, Whiteman MK, Marchbanks PA, et al. Progestin-only contraception and thromboembolism: A systematic review. Contraception 2016; 94:678.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/38\" class=\"nounderline abstract_t\">ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006; 107:1453.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/39\" class=\"nounderline abstract_t\">Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/40\" class=\"nounderline abstract_t\">Kjos SL, Peters RK, Xiang A, et al. Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus. JAMA 1998; 280:533.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/41\" class=\"nounderline abstract_t\">Furlong LA. Ectopic pregnancy risk when contraception fails. A review. J Reprod Med 2002; 47:881.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/42\" class=\"nounderline abstract_t\">Caird LE, Reid-Thomas V, Hannan WJ, et al. Oral progestogen-only contraception may protect against loss of bone mass in breast-feeding women. Clin Endocrinol (Oxf) 1994; 41:739.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/43\" class=\"nounderline abstract_t\">Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999; 91:1131.</a></li><li><a href=\"https://www.uptodate.com/contents/progestin-only-pills-pops-for-contraception/abstract/44\" class=\"nounderline abstract_t\">Breast cancer and hormonal contraceptives: further results. Collaborative Group on Hormonal Factors in Breast Cancer. Contraception 1996; 54:1S.</a></li><li class=\"breakAll\">World Health Organization. Medical Eligibility Criteria for Contraceptive Use, 5th Edition, World Health Organization, 2015.</li></ol></div><div id=\"topicVersionRevision\">Topic 5461 Version 24.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H22\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H15275427\" id=\"outline-link-H15275427\">FORMULATIONS</a><ul><li><a href=\"#H15275506\" id=\"outline-link-H15275506\">Norethindrone</a></li><li><a href=\"#H15275512\" id=\"outline-link-H15275512\">Desogestrel</a></li></ul></li><li><a href=\"#H2\" id=\"outline-link-H2\">MECHANISM OF ACTION</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">EFFICACY</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">ADMINISTRATION</a><ul><li><a href=\"#H407447885\" id=\"outline-link-H407447885\">Candidates for use of POPs</a><ul><li><a href=\"#H1073173877\" id=\"outline-link-H1073173877\">- Women in whom estrogen is contraindicated</a></li></ul></li><li><a href=\"#H14876562\" id=\"outline-link-H14876562\">Patient evaluation</a></li><li><a href=\"#H407447879\" id=\"outline-link-H407447879\">Initiation</a></li><li><a href=\"#H407447977\" id=\"outline-link-H407447977\">Timing doses and missed pills</a></li><li><a href=\"#H407447920\" id=\"outline-link-H407447920\">Reducing barriers to use</a></li><li><a href=\"#H407447946\" id=\"outline-link-H407447946\">Follow-up</a></li></ul></li><li><a href=\"#H5\" id=\"outline-link-H5\">SIDE EFFECTS</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">RISKS AND BENEFITS</a><ul><li><a href=\"#H12\" id=\"outline-link-H12\">Effect on cardiovascular risk</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Effect on carbohydrate metabolism</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">Ectopic pregnancy risk</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">Effect on bone mineral density</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">Older reproductive age women</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">Effect on cancer risk</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">Effect on sexually transmitted infections</a></li><li><a href=\"#H1073173918\" id=\"outline-link-H1073173918\">Noncontraceptive benefits</a></li></ul></li><li><a href=\"#H19\" id=\"outline-link-H19\">USE AFTER ABORTION OR DELIVERY</a></li><li><a href=\"#H1789383836\" id=\"outline-link-H1789383836\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H21\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H22\" id=\"outline-link-H22\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"OBGYN/5461|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=OBGYN/67567\" class=\"graphic graphic_table\">- Questions used to assess possibility of pregnancy</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=depot-medroxyprogesterone-acetate-for-contraception\" class=\"medical medical_review\">Depot medroxyprogesterone acetate for contraception</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=etonogestrel-contraceptive-implant\" class=\"medical medical_review\">Etonogestrel contraceptive implant</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=intrauterine-contraception-candidates-and-device-selection\" class=\"medical medical_review\">Intrauterine contraception: Candidates and device selection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-unscheduled-bleeding-in-women-using-contraception\" class=\"medical medical_review\">Management of unscheduled bleeding in women using contraception</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hormonal-methods-of-birth-control-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Hormonal methods of birth control (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=postpartum-contraception-initiation-and-methods\" class=\"medical medical_review\">Postpartum contraception: Initiation and methods</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=risks-and-side-effects-associated-with-estrogen-progestin-contraceptives\" class=\"medical medical_review\">Risks and side effects associated with estrogen-progestin contraceptives</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-contraception\" class=\"medical medical_society_guidelines\">Society guideline links: Contraception</a></li></ul></div></div>","javascript":null}